Download PDF
Klin Padiatr 2015; 227(03): 105-107
DOI: 10.1055/s-0035-1548751
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Progress in the Treatment of Ewing Sarcoma: Are the Rumors of the Demise of Cytotoxic Chemotherapy Premature?

Fortschritte bei der Behandlung von Ewing-Sarkomen: Hat die zytotoxische Chemotherapie das Ende der Fahnenstange erreicht?
G. Rosen
Further Information

Publication History

Publication Date:
18 May 2015 (online)

Also available at
   Permissions and Reprints

In this issue, Bollling et. al. review the development of treatment of Ewing sarcoma as it evolved over the past 30 years of clinical trials in Europe, largely under the leadership of Heribert Jurgens to whom this review is dedicated. The 44 authors were teachers, colleagues, students and co-investigators of Jurgens. The authors attribute the ability to make progress in the treatment of Ewing sarcoma through the establishment of larger and still larger cooperative studies in order to demonstrate statistically significant advances in the treatment of this rare disease.

 

  • References

  • 1 Al-Faris N, Al Harbi T, Goia C et al. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?. Pediatr Blood Cancer 2007; 49: 190-195
    CrossrefPubMedGoogle Scholar
  • 2 Casey DA, Wexler LH, Merchant MS et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009; 53: 1029-1034
    CrossrefPubMedGoogle Scholar
  • 3 Craft A, Cotterill S, Malcolm A et al. Ifosfamide-containing chemotherapy in Ewing’s sarcoma: The Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J Clin Oncol 1998; 16: 3628-3633
    PubMedGoogle Scholar
  • 4 Eilber FC, Eilber FR, Eckardt J et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004; 240: 686-695 discussion 695-687
    PubMedGoogle Scholar
  • 5 Granowetter L, Womer R, Devidas M et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 2009; 27: 2536-2541
    CrossrefPubMedGoogle Scholar
  • 6 Kushner BH, Kramer K, Modak S et al. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009; 53: 17-22
    CrossrefPubMedGoogle Scholar
  • 7 Le Deley MC, Paulussen M, Lewis I et al. Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. J Clin Oncol 2014; DOI: 10.1200/JCO.2013.54.4833.
    PubMedGoogle Scholar
  • 8 Milano GM, Cozza R, Ilari I et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesu Children’s Hospital experience. Cancer 2006; 106: 1838-1845
    CrossrefPubMedGoogle Scholar
  • 9 Nesbit Jr ME, Perez CA, Tefft M et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: an Intergroup Study. National Cancer Institute monograph 1981; 255-262
    PubMedGoogle Scholar
  • 10 Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-2384
    CrossrefPubMedGoogle Scholar
  • 11 Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: Final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 2001; 19: 1818-1829
    PubMedGoogle Scholar
  • 12 Paulussen M, Craft AW, Lewis I et al. Results of the EICESS-92 study: Two randomized trials of Ewing’s sarcoma treatment – Cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26: 4385-4393
    CrossrefPubMedGoogle Scholar
  • 13 Rosen G, Caparros B, Nirenberg A et al. Ewings-Sarcoma – Ten-Year Experience with Adjuvant Chemotherapy. Cancer 1981; 47: 2204-2213
    CrossrefPubMedGoogle Scholar
  • 14 Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br J Cancer 2000; 82: 1636-1645
    CrossrefPubMedGoogle Scholar
  • 15 Skinner R, Parry A, Price L et al. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer 2010; 54: 983-989
    CrossrefPubMedGoogle Scholar
  • 16 Van Winkle P, Angiolillo A, Krailo M et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer 2005; 44: 338-347
    CrossrefPubMedGoogle Scholar